Literature DB >> 10501501

Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia.

Hetty J Bontkes1, Tanja D de Gruijl1, Astrid Bijl1, René H M Verheijen1, Chris J L M Meijer1, Rik J Scheper1, Peter L Stern2, Julie E Burns3, Norman J Maitland3, Jan M M Walboomers1.   

Abstract

T-cell-mediated immune responses against mucosal oncogenic types of human papillomaviruses (HPV) are thought to play a role in the control of the virus infection and its associated cervical lesions. The in vitro production of interleukin-2 by T-helper (Th) cells in response to the C-terminal and N-terminal domains of the HPV-16 E2 protein was determined in 74 women with cytological evidence of premalignant cervical epithelial neoplasia who participated in a non-intervention follow-up (FU) study. Cross-sectional analysis at the end of FU showed that Th cell responses against the C-terminal domain were associated with evidence of previous or present HPV-16 infection as compared to patients with no evidence of any HPV infection (18.9% versus 0%, P = 0.039). Th cell responses against the N-terminal domain were not associated with evidence of HPV-16 infection. No association with disease outcome was observed with Th cell responses against either of the E2 protein domains. However, longitudinal analysis revealed that Th cell responses against the C-terminal domain frequently occur at the time of virus clearance. Whether these responses are responsible for the clearance of the virus is not known.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10501501     DOI: 10.1099/0022-1317-80-9-2453

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

Review 2.  HPV Vaccines: today and in the Future.

Authors:  Anna-Barbara Moscicki
Journal:  J Adolesc Health       Date:  2008-10       Impact factor: 5.012

3.  Immunosuppressive tumor microenvironment in cervical cancer patients.

Authors:  Sytse J Piersma
Journal:  Cancer Microenviron       Date:  2011-05-31

4.  Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women.

Authors:  Mayumi Nakagawa; Raphael Viscidi; Ian Deshmukh; Maria Da Costa; Joel M Palefsky; Sepideh Farhat; Anna-Barbara Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

5.  Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection.

Authors:  Sepideh Farhat; Mayumi Nakagawa; Anna-Barbara Moscicki
Journal:  Int J Gynecol Cancer       Date:  2009-05       Impact factor: 3.437

6.  A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.

Authors:  Peggy J de Vos van Steenwijk; Tamara H Ramwadhdoebe; Margriet J G Löwik; Caroline E van der Minne; Dorien M A Berends-van der Meer; Lorraine M Fathers; A Rob P M Valentijn; Jaap Oostendorp; Gert Jan Fleuren; Bart W J Hellebrekers; Marij J P Welters; Mariette I van Poelgeest; Cornelis J M Melief; Gemma G Kenter; Sjoerd H van der Burg
Journal:  Cancer Immunol Immunother       Date:  2012-06-09       Impact factor: 6.968

Review 7.  Chronic immune activation and inflammation as the cause of malignancy.

Authors:  K J O'Byrne; A G Dalgleish
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

8.  Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.

Authors:  G Forsberg; L Ohlsson; T Brodin; P Björk; P A Lando; D Shaw; P L Stern; M Dohlsten
Journal:  Br J Cancer       Date:  2001-07-06       Impact factor: 7.640

9.  T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia.

Authors:  J C Steele; C H Mann; S Rookes; T Rollason; D Murphy; M G Freeth; P H Gallimore; S Roberts
Journal:  Br J Cancer       Date:  2005-07-25       Impact factor: 7.640

10.  Cytokine release in HR-HPV(+) women without and with cervical dysplasia (CIN II and III) or carcinoma, compared with HR-HPV(-) controls.

Authors:  Aagje G Bais; Ilse Beckmann; Patricia C Ewing; Marinus J C Eijkemans; Chris J L M Meijer; Peter J F Snijders; Theo J M Helmerhorst
Journal:  Mediators Inflamm       Date:  2007       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.